Core Viewpoint - UBS's report indicates that Hong Kong residents exhibit a more cautious sentiment regarding investment and consumption intentions than expected, with a decrease in the number of respondents holding a positive outlook on the economic prospects for the next 12 months [1] Group 1: Economic Sentiment - Respondents' financial situations have remained stable over the past 12 months, but their positive outlook on Hong Kong's economic prospects has diminished, which has suppressed consumption intentions [1] - The most concerning issues for respondents include rising living costs and job security [1] Group 2: Investment Outlook - Investment intentions have remained relatively stable, supported by the positive momentum in Hong Kong's financial sector, which is expected to bolster overall economic and labor demand [1] - The robust performance of Hong Kong and A-shares is anticipated to create a positive wealth effect, suggesting that resident confidence may improve by 2026 [1] Group 3: Sector Recommendations - UBS maintains a positive outlook on the real estate and financial sectors, removing Henderson Land Development (00012) from its preferred stock list and replacing it with Sino Land Company (00083) due to higher dividend visibility [1] - Other stocks included in the preferred list are AIA Group (01299), Swire Properties (01972), Galaxy Entertainment (00027), and Wynn Macau (01128) [1]

瑞银发表研报指，澳门过去7日的日均博彩收入约为6.93亿澳门元，与前7日约7亿澳门元大致持平，使 本月至今的日均博彩收入达到约7.12亿澳门元，按年增长约21%，按月上升约6%，升幅高于2015至2019 年同期平均的2%。至于即将来临的农历新年假期，该行追踪的32间酒店中，有27间显示客房已售罄， 情况与去年同期大致相若。该行维持银河娱乐及永利澳门为行业首选，目标价分别为46.9港元及8.9港 元，均予"买入"评级。 ...

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies. Core Insights - The report highlights significant developments in the overseas pharmaceutical sector, including the collaboration between Insilico Medicine and Heng Tai Biopharma to develop a novel NLRP3 inhibitor for central nervous system diseases [2][6]. - The report notes that MicroPort Robotics expects a revenue growth of approximately 110%-120% year-on-year for 2025, with an adjusted net loss not exceeding 240 million yuan, representing a reduction of over 50% [5][6]. - GSK has reached a final agreement to acquire RAPT Therapeutics for approximately 2.2 billion USD, focusing on a long-acting monoclonal antibody currently in clinical trials [7][8]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biopharma have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with both companies holding 50% global rights [2][6]. - The Hong Kong Stock Exchange has approved the full circulation of 182,645,856 H shares for Fuhong Hanlin, representing about 33.61% of the company's total issued shares as of January 19 [2][6]. - The new drug application for TLX591-CDx, a radiopharmaceutical for prostate cancer diagnosis, has been accepted by the NMPA [2][6]. 2. Company Updates - MicroPort Robotics has reported over 180 commercial orders and more than 120 installations globally as of January 21 [5][6]. - Legend Biotech, a joint venture of Genscript Biotech, reported a trade sales net of approximately 555 million USD for the quarter ending December 31, 2025 [5][6]. - GSK's acquisition of RAPT Therapeutics includes a payment of 58.00 USD per share, with an expected upfront investment of 1.9 billion USD after cash adjustments [7][8]. 3. Market Performance - The Hang Seng Healthcare Index fell by 4.35%, underperforming the Hang Seng Index by 3.26 percentage points [4]. - The report indicates a strong performance in the overseas education sector, with GMV for Dongfang Zhenxuan reaching approximately 310 million yuan, a 42.8% increase week-on-week [15][16]. 4. Recommendations - The report suggests focusing on innovative drugs and the ongoing clinical progress of key pipelines from companies such as BeiGene, Innovent Biologics, and others [12]. - It also recommends monitoring the performance of educational companies like Dongfang Zhenxuan and China Oriental Education, which are expected to benefit from improved operational strategies and increased enrollment [16].

Core Viewpoint - Goldman Sachs reports that several Macau gaming stocks are set to announce their Q4 2025 earnings, with investors expected to focus on profit trends amid concerns over additional spending for the National Games in November and intense competition [1] Industry Summary - The firm anticipates a quarterly and year-on-year increase in industry EBITDA by 4% and 13% respectively, compared to a quarterly and year-on-year increase in total gaming revenue of 6% and 14%, driven by rising operating expenses and a shift towards lower-margin VIP gaming [1] Company Summaries - Galaxy Entertainment (00027) is expected to see its EBITDA rise by 28% quarter-on-quarter to $550 million, attributed to a higher VIP win rate [1] - MGM China (02282) is projected to have its EBITDA increase by 8% quarter-on-quarter to $328 million, due to a robust recovery in gaming revenue [1] - Sands China (01928) is forecasted to experience a 4% quarter-on-quarter EBITDA increase to $628 million, as retail revenue growth is offset by higher operating expenses and promotional costs [1] Future Outlook - For 2026, the firm expects overall gaming revenue to increase by 8% year-on-year and EBITDA to rise by 10%, leading to industry EBITDA and recurring free cash flow reaching $9.1 billion and $6.4 billion respectively, nearing pre-COVID levels [1] - The firm believes that the current industry valuations remain attractive and reiterates a "buy" rating for Galaxy Entertainment, MGM China, and Sands China [1]

Core Viewpoint - Goldman Sachs reports that several Macau gaming stocks are set to announce their Q4 2025 earnings, with investors expected to focus on profit trends amid concerns over additional spending for the November National Games and intense competition [1] Industry Summary - The firm anticipates a quarterly and year-on-year increase in industry EBITDA by 4% and 13% respectively, compared to a quarterly and year-on-year rise in total gaming revenue of 6% and 14% [1] - The increase in operating expenses and the shift of gaming revenue towards the lower-margin VIP segment are noted as contributing factors [1] Company-Specific Insights - Galaxy Entertainment (00027) is expected to see its EBITDA rise by 28% quarter-on-quarter to $550 million, driven by a higher VIP win rate [1] - MGM China (02282) is projected to have an EBITDA increase of 8% quarter-on-quarter to $328 million, attributed to a robust recovery in gaming revenue [1] - Sands China (01928) is forecasted to experience a 4% quarter-on-quarter EBITDA increase to $628 million, as retail revenue growth is offset by higher operating expenses and promotional costs [1] Future Outlook - For 2026, the overall gaming revenue is expected to increase by 8% year-on-year, with EBITDA rising by 10%, leading to industry EBITDA and recurring free cash flow reaching $9.1 billion and $6.4 billion respectively, nearing pre-COVID levels [1] - The firm believes that the current industry valuations remain attractive and reiterates a "buy" rating for Galaxy Entertainment, MGM China, and Sands China [1]

Investment Rating - The report maintains a "Positive" outlook on the overseas pharmaceutical sector, highlighting significant developments and collaborations in the industry [1]. Core Insights - The collaboration between Insilico Medicine and Heng Tai Biologics to develop an innovative brain-penetrating NLRP3 inhibitor is a key highlight, with potential applications in treating central nervous system diseases [2][7]. - The approval of full circulation for Fuhong Hanlin's H shares is noted, which involves a significant number of shares and stakeholders [2][7]. - The report emphasizes the strong revenue growth projections for companies like MicroPort Robotics and King’s Ray Biotech, with expected revenue increases of approximately 110%-120% year-on-year for 2025 [6][10]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biologics have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with a 50% global rights share and potential milestone payments exceeding HKD 500 million [2][7]. - Fuhong Hanlin's H shares have received approval for full circulation, involving 182,645,856 shares, which represents about 33.61% of the company's total issued shares [2][7]. 2. Company Performance Updates - MicroPort Robotics anticipates a revenue increase of 110%-120% for 2025, with adjusted net losses expected to narrow by over 50% [6][10]. - King’s Ray Biotech's joint venture, Legend Biotech, is projected to generate approximately USD 555 million in trade sales for the quarter ending December 31, 2025 [6][10]. 3. Recent Developments in Overseas Pharmaceutical Companies - GSK has reached an agreement to acquire RAPT Therapeutics for approximately USD 2.2 billion, focusing on a long-acting IgE monoclonal antibody currently in clinical trials [3][8]. - Corvus has reported positive results from a Phase I trial of its ITK inhibitor for moderate to severe atopic dermatitis, showing good safety and efficacy [3][9]. - Eli Lilly's FRα ADC has received breakthrough therapy designation from the FDA for treating platinum-resistant ovarian cancer [3][9]. 4. Recommendations - The report suggests monitoring innovative drug companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and Fuhong Hanlin [13]. - It also highlights the importance of ongoing clinical progress in innovative pipelines for pharmaceutical companies transitioning towards innovation [13].

Group 1 - The core viewpoint is that Galaxy Entertainment is expected to increase its market share in 2026, following a rise in net revenue and adjusted EBITDA in Q4 2025 [1] - In Q4 2025, Galaxy Entertainment recorded net revenue of HKD 12.2 billion, a year-on-year increase of 14%, with adjusted EBITDA also rising by 14% to HKD 3.3 billion [1] - The company anticipates a market share of approximately 20% for the full year of 2025, maintaining its position as the second-largest player in the industry [1] Group 2 - Macau's gaming revenue is projected to grow by 9.1% year-on-year to MOP 247.4 billion in 2025, with a significant increase of 13.8% in the second half of the year [2] - The upcoming longer Spring Festival holiday in 2026 is expected to boost travel demand from mainland citizens, benefiting Macau's tourism and gaming sectors [2] - Galaxy Entertainment is likely to attract more investor interest compared to competitors, due to increased brand fees and geopolitical considerations affecting peers [2] Group 3 - The current valuation of Galaxy Entertainment is at 10.6 times the 2026 EV/EBITDA, which is considered low compared to the pre-pandemic range of 10.0 to 14.0 times [3] - There is potential for further upward adjustment in valuation as the company's performance continues to improve [3]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of HKD 45.50, indicating an upside potential of 12.6% from the current price of HKD 40.42 [5][8]. Core Insights - The company recorded a net revenue of HKD 12.2 billion for Q3 2025, representing a year-on-year increase of 14%. Adjusted EBITDA also rose by 14% to HKD 3.3 billion, with a normalized net win rate leading to a 7% increase in adjusted EBITDA [1]. - The company's market share is estimated to be around 20% for the full year of 2025, maintaining its position as the second-largest player in the industry. Management indicated an increase in market share for Q4 2025, with expectations for further growth in 2026 due to the utilization of new projects opening in December 2023 [1]. - Macau's gaming revenue is projected to grow by 9.1% year-on-year to MOP 247.4 billion in 2025, with a significant increase of 13.8% in the second half of 2025. The upcoming longer Spring Festival holiday in 2026 is expected to boost travel demand from mainland citizens, benefiting the tourism sector and the company [2]. - Competitors are facing increased brand fees and geopolitical concerns, which may lead to a preference for the company among investors. MGM China announced a new brand agreement that doubles its brand fees, raising market concerns for other competitors [3]. - The company's current valuation is at 10.6 times the 2026 EV/EBITDA, which is considered low compared to the pre-pandemic range of 10.0 to 14.0 times, suggesting potential for valuation re-rating as performance improves [4]. Financial Summary - Revenue projections for the company are as follows: FY22: HKD 11.474 billion, FY23: HKD 35.684 billion, FY24: HKD 43.432 billion, FY25E: HKD 48.574 billion, FY26E: HKD 52.232 billion [5]. - EBITDA projections are: FY22: HKD (0.553) billion, FY23: HKD 9.955 billion, FY24: HKD 12.188 billion, FY25E: HKD 14.020 billion, FY26E: HKD 14.971 billion [5].

Core Viewpoint - Morgan Stanley's research report indicates a slight decline in profit margins for the Macau gaming industry in Q4 2025 due to unfavorable business mix changes (higher proportion of VIP customers) and increased operating expenses [1] Industry Summary - The average adjusted property EBITDA for the industry is expected to increase by 4% quarter-on-quarter and 13% year-on-year in Q4, aligning with market expectations [1] Company Summary - Morgan Stanley is optimistic about Galaxy Entertainment and Sands China, both rated "Overweight" [1] - The rating for Melco Resorts China was downgraded to "In Line with the Market" in December due to high royalty expenses [1] - A "Underweight" rating was assigned to SJM Holdings [1]

Group 1 - The core viewpoint of the articles indicates a rebound in Hong Kong's gaming stocks, particularly in the Macau gaming sector, with significant increases in stock prices for companies like Melco International Development and Galaxy Entertainment [1] - According to a report by Jefferies, Macau's gaming revenue has shown strong growth, with an average daily revenue of 693 million MOP as of January 11, reflecting an 18% year-on-year increase [1] - Jefferies' industry survey suggests that Macau's gaming revenue is expected to grow by 15% to 21% year-on-year for the entire month of January [1] Group 2 - Specific stock performance includes Melco International Development rising by 3.5%, Galaxy Entertainment and Huayi Tencent Entertainment increasing by over 3%, and Sands China and Wynn Macau rising by over 2% [2] - The report highlights a shift in investor preference towards U.S. regional gaming stocks, although Jefferies maintains that the fundamentals of stocks primarily operating in Macau are superior to their peers [1] - Jefferies continues to favor Wynn and Sands in the U.S. market, as well as Galaxy Entertainment and Sands China in the Hong Kong market [1]